Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.50
Bid: 43.00
Ask: 44.00
Change: 3.00 (7.41%)
Spread: 1.00 (2.326%)
Open: 40.50
High: 45.00
Low: 40.50
Prev. Close: 40.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: M&S Gains, B&M Loses On Jefferies Ratings

Wed, 03rd Jun 2020 10:56

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.

----------

FTSE 250 - WINNERS

----------

Chemring Group, up 24%. The defence technology company reported 37% revenue growth in the six months to the end of April to GBP191.0 million, taking pretax profit up to GBP19.0 million from GBP4.3 million a year ago. Chemring increased its interim payout by 8% to 1.3 pence a share. The company said its performance in the first half of its current financial year was ahead of expectations, reflecting strong performance in both segments of its business and some positive timing differences. Chemring reported good progress in securing new business in the UK, US and Australia for the supply of global countermeasures. Looking forward, Chemring said all of its businesses have remained open despite the challenges presented by Covid-19. Its full-year expectations are unchanged, despite the challenging environment, with about 95% of expected second-half revenue in the order book or delivered to date.

----------

Marks & Spencer Group, up 5.8%. Jefferies raised the UK retailer to Buy from Hold.

----------

FTSE 250 - LOSERS

----------

B&M European Value Retail, down 1.3%, Jefferies downgraded the UK retailer to Hold from Buy.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Cadence Minerals, up 42%. The company - which invests in lithium mining projects - said its joint venture partner Hastings Technology Metals entered into binding master agreement with the German automotive supplier Schaeffler Technologies for the targeted supply of its MREC, the product mined and processed from Yangibana project in the Gascoyne region, Western Australia. Hastings obligation is to supply a substantial volume of MREC over a period of 10 years as initial period. Cadence owns 30% of the Yangibana, Yangibana North, Gossan, Hook, Kanes Gossan and Lions Ear rare earth deposit, which form part of the Yangibana rare earth deposit. "This contract represents a very important milestone in the development of Hastings as an emerging supplier of rare earth carbonate from Australia to Germany, an industrialised nation with a growing demand for a critical raw material used in many advanced technologies where a permanent magnet is needed," said Hastings Chair Charles Lew.

----------

Bluerock Diamonds, up 22%. The diamond producer reported no cases of Covid-19 at the Kareevlei diamond mine in the Kimberley region of South Africa. Bluerock said production averaged almost 2,000 tons a day since May 11 to bring total to 41,500 tons, which is 65% higher than the average daily production in the prior record quarter to the end of 2019. "The modifications made to the primary crushing circuit and the introduction of the third pan together with the processing of softer near surface material have allowed us to increase production at minimal cost whilst also reducing operating costs," said Executive Chair Mike Houston.

----------

React Group, up 12% at 1.70 pence. The carpet cleaning company said it placed 83.1 million shares at a price of 1.5p each, raising GBP1.3 million before expenses. The placing was materially oversubscribed following demand from both new and existing institutional and other investors. React said it intends to use the proceeds from the fundraising to strengthen its sales and marketing activities, and support a growing contract pipeline and accelerate organic growth. In addition, the proceeds will go towards additional working capital and to strengthen the company's balance sheet to support its aspiration to secure larger contracts. "This oversubscribed fundraise recognises the progress achieved so far and provides React with the working capital and balance sheet strength to support ambitions for further sustainable and profitable growth," said Chief Executive Shaun Doak.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Sareum Holdings, down 16% at 0.59p. The pharmaceutical company said it has completed a fundraising, comprising a placing by Hybridan in conjunction with an offer via PrimaryBid. Sareum said it raised GBP303,722 through a shares issue at a price of 0.6p per share. Accordingly, combined with the placing, the company has raised a total of GBP1.0 million. "We believe that our TYK2/JAK1 inhibitor candidates - SDC-1801 and SDC-1802 - represent exciting prospects. The way they act continues to be a focus for the broader industry interested in treating autoimmune diseases, cancer and more recently in addressing the severe respiratory symptoms associated with advanced Covid-19. These new funds will be used to advance their preclinical studies targeting completion in at least one indication late this year, pending successful progress," said Chief Executive Tim Mitchell.

----------

Beowulf Mining, down 9.2%. The exploration and development company said Chief Executive Kurt Budge has written to Ibrahim Baylan, minister for Business, Industry and Innovation, the government of Sweden. "Beowulf has several thousand Swedish shareholders, who own over 67 per cent of the company. They have witnessed the government's unacceptable mishandling of the Kallak application and false promises; the opportunity cost of which is incalculable. They are demanding the government be fully transparent now and remove all uncertainty as to when a decision on Kallak will be taken," Budge wrote. Beowulf said it is ready to play its part in Sweden's economic recovery, to advance Kallak in partnership with the community in Jokkmokk.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
26 Feb 2014 12:01

Sareum Shares Drop As Pretax Loss Widens

LONDON (Alliance News) - Shares in Sareum Holdings PLC slid 12% Wednesday as its pretax loss widened in the half-year ended December 31, 2013. The specialist cancer drug discovery and development business posted a pretax loss of GBP375,000, widened from GBP305,000 in the previous year, due

Read more
22 Jan 2014 10:27

Sareum Receives Patent As It Progresses Cancer Treatment To Trials

LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it had received a patent from the US Patent and Trademark Office for one of the inventions associated to its CHK1 cancer treatment programme. The patent covers compounds developed by Sareum and Cancer Research UK-funded scient

Read more
2 Dec 2013 14:17

Sareum Holdings does cancer drug deal in China

Cancer drug developer Sareum Holdings has signed a deal with a Chinese medical university to progress its Aurora+FLT3 cancer programme. Sareum has granted the Hebei Medical University Biomedical Engineering Center exclusive rights to carry out pre-clinical and clinical studies within Greater China

Read more
1 Nov 2013 12:52

UK WINNERS & LOSERS: Vodafone Up But Meggitt Slides After Warning

Read more
1 Nov 2013 12:34

Sareum raises funds for further drug development

Sareum Holdings, a cancer drug discovery and development business, has placed 278.5m shares at 0.6p each, it announced Friday. The group raised a conditional £1.67m before expenses from the placing, which it said was oversubscribed. The proceeds of the placing will provide funds to facilitate the

Read more
1 Nov 2013 10:48

CORRECT: Sareum Slides After Placing To Raise Funds For Development Programmes

Read more
1 Nov 2013 10:17

Sareum Slides After Placing To Raise Funds For Development Programmes

Read more
24 Sep 2013 07:35

Sareum Holdings In Co-Development Deal For Cancer Treatment

Read more
22 Apr 2013 08:06

Sareum Holdings and SRI International develop drug for inflammatory diseases

Cancer drug discovery business Sareum Holdings has entered into a co-development agreement with research institute SRI International. The two have joined forces to advance Sareum's Tyrosine Kinase 2 (TYK2) small molecule drug discovery programme for readiness in human clinical trials. Research wi

Read more
18 Feb 2013 08:21

Sareum shares fall following interims and research update

Shares in AIM-listed Sareum Holdings, the specialist cancer drug discovery business, fell sharply on Monday morning after the company unveiled its half yearly results alongside a research update. Cash at bank as of December 31st fell 28% to £380,000 and the company reported a loss on ordinary activ

Read more
7 Feb 2013 08:27

Sareum share price climbs on US patent grant announcement

The share price of AIM-listed specialist cancer drug discovery business Sareum Holdings jumped sharply on Thursday after the company announced that a patent was due to be awarded in the US for one of its key drug discovery inventions. The patent, which is expected on February 19th, relates to compo

Read more
12 Dec 2012 10:40

Sareum share price plummets ahead of AGM

The likelihood that specialist cancer drug discovery business Sareum will conclude a deal to commercialise a research programme this year has fallen, according to an announcement made ahead of its annual general meeting (AGM) on Wednesday morning. During the AGM, Dr. Paul Harper, the company's Chai

Read more
10 Sep 2012 14:37

Small caps round-up: Sareum, Lonrho, FFastFill

Sareum, a specialist cancer drug discovery business, has entered into a four million pound Standby Equity Distribution Agreement (SEDA) with YA Global Master, an investment fund to provide a flexible source of future funding to the company to support its on-going drug research activities. It will a

Read more
7 Aug 2012 11:25

Small caps round-up: YouGov, Sareum and InterQuest...

Environmental Recycling Technologies, which owns the rights to the Powder Impression Moulding (PIM) process which is capable of converting mixed waste plastics into commercially viable products, has confirmed that its US parent application, entitled 'Process for Forming Plastic, Apparatuses for Form

Read more
19 Jul 2012 12:07

Small caps round-up: Byotrol, sareum, KDD ...

Byotrol, an anti-microbial hygiene company, has continued to make progress and has maintained the momentum seen in the second half of last year into the current financial year. The balance sheet continues to remain strong and is well positioned to its objective of positive cash generation at the ear

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.